Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects - Ramanathan, Srini; Custodio, Joseph M; Wei, Xuelian; Wang, Hui; Fordyce, Marshall; Dave, Ami; Ling, Kah Hiing J; Szwarcberg, Javier; Kearney, Brian P (Journal of acquired immune deficiency syndromes (1999), 2016)
Keywords: Adolescent; Adult; Anti-HIV Agents - adverse effects; Anti-HIV Agents - pharmacokinetics; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - pharmacokinetics; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - pharmacokinetics; Female; Healthy Volunteers; Humans; Male; Middle Aged; Treatment Outcome; Young Adult